In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

Stocks are freefalling this afternoon, as President Donald Trump's tariffs go into effect and trade partners retaliate ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Private Advisor Group LLC trimmed its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 38.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange ...

The best long-term investments might not be what you think.

After hours: February 28 at 7:39:11 PM EST ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

After hours: 7:45:25 p.m. EST ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.